Pharma’s Biggest Dealmakers Face More Than M&A Risks – Bloomberg
Bloomberg |
Pharma's Biggest Dealmakers Face More Than M&A Risks
Bloomberg The age of gene therapies – medicines that work by altering human genes – is arriving, and with it, the potential for curing diseases with one-and-done treatments. But parts of the pharma world, including some of this year's biggest dealmakers, are … |
